德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment 2021-04-29 08:34
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL 2021-04-13 08:00
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations 2021-04-12 08:00
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma 2021-04-06 08:00
Antengene Announces Financial Results for Full Year 2020 2021-03-26 08:00
Antengene Appoints Kevin Lynch as Chief Medical Officer 2021-03-25 23:26
Antengene Appoints Bo Shan as Chief Scientific Officer 2021-03-25 22:36
Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021 2021-03-22 08:00
Antengene Included in the Shenzhen-Hong Kong Stock Connect 2021-03-15 09:40
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea 2021-03-15 08:00
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index 2021-03-01 08:00
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index 2021-03-01 08:00
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA 2021-02-24 08:00
Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage 2021-02-01 08:09
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM 2021-01-28 08:00
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM 2021-01-28 08:00
Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study 2021-01-25 08:20
Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference 2021-01-11 07:26
Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer 2021-01-05 08:00
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL 2021-01-04 08:00
1 5 6 7 8 9